Pediatric Clinics of North America - CIPERJ

More documents

Recommendations

Info

DECISION ANALYSIS IN PEDIATRIC HEMATOLOGY 303 Acknowledgments Special thanks to Dr. Kelly Kelleher for his thoughtful review of this article and to Ms. Christine Riley for her administrative support. References [1] Hulley SB. Research using existing data: secondary data analysis, ancillary studies, and systematic reviews. In: Hulley SB, Cummings SR, Browner WS, editors. Designing clinical research. 2nd edition. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 195–212. [2] Cook DJ, Greengold NL, Ellrodt AG, et al. The relation between systematic reviews and practice guidelines. Ann Intern Med 1997;127:210–6. [3] Weinstein MC, Fineberg HV. Clinical decision analysis. Philadelphia: W.B. Saunders; 1980. [4] Albert DA. Decision theory in medicine: a review and critique. Milbank Mem Fund Q Health Soc 1978;56:362–401. [5] Detsky AS, Naglie G, Krahn MD, et al. Primer on medical decision analysis: part 1–getting started. Med Decis Making 1997;17:123–5. [6] Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med 1998;339:5–11. [7] Male C, Chait P, Ginsberg JS, et al. Comparison of venography and ultrasound for the diagnosis of asymptomatic deep vein thrombosis in the upper body in children: results of the PARKAA study. Prophylactic antithrombin replacement in kids with all treated with asparaginase. Thromb Haemost 2002;87:593–8. [8] Maxwell D. Improving hard decisions: biennial survey of decision analysis software offers side-by-side comparison of critical O.R. tools. OR/MS Today, 2006;33(6). [9] Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993;13:322–38. [10] Burd RS, Sonnenberg FA. Decision analysis: a basic overview for the pediatric surgeon. Semin Pediatr Surg 2002;11:46–54. [11] Bohn RL, Colowick AB, Avorn J. Probabilities, costs, and outcomes: methodological issues in modelling haemophilia treatment. Haemophilia 1999;5:374–7. [12] Drug topics red book. Montvale (NY): Medical Economics; 2006. [13] US Department of Health and Human Services. Centers for Medicare and Medicaid services. Available at: http://www.cms.hhs.gov. Accessed February 14, 2008. [14] Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996;276:1253–8. [15] US Department of Labor. Bureau of Labor Statistics data. Available at: http://www.bls.gov/ data/home.htm. Accessed February 14, 2008. [16] Drummond M. Basic types of economic evaluation. In: Drummond MF, Obrien B, Stoddard GL, et al, editors. Methods for the economic evaluation of health care programmes. 2nd edition. Oxford (UK): Oxford University Press; 1997. p. 6–26. [17] Griebsch I, Coast J, Brown J. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health. Pediatrics 2005;115:e600–14. [18] Drummond MF, O’Brien B, Stoddart GL, et al. Methods for the economic evaluation of health care programmes. 2nd edition. Oxford (England); New York: Oxford University Press; 1997. [19] Health Decision Strategies, LLC. Decision tools, questionnaires, and surveys. Available at: http://www.healthstrategy.com/objectiv.htm. Accessed February 15, 2008. [20] Gold MR, Franks P, McCoy KI, et al. Toward consistency in cost-utility analyses: using national measures to create condition-specific values. Med Care 1998;36:778–92. [21] Tengs TO, Wallace A. One thousand health-related quality-of-life estimates. Med Care 2000; 38:583–637.
304 O’BRIEN [22] Richardson WS, Detsky AS. Users’ guides to the medical literature. VII. How to use a clinical decision analysis. B. What are the results and will they help me in caring for my patients Evidence based medicine working group. JAMA 1995;273:1610–3. [23] Weinstein MC, Fineberg HV. Clinical decision analysis. Philadelphia: W.B. Saunders; 1980. [24] Elkin EB, Vickers AJ, Kattan MW. Primer: using decision analysis to improve clinical decision making in urology. Nat Clin Pract Urol 2006;3:439–48. [25] Hirth RA, Chernew ME, Miller E, et al. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making 2000;20:332–42. [26] Ubel PA, Hirth RA, Chernew ME, et al. What is the price of life and why doesn’t it increase at the rate of inflation Arch Intern Med 2003;163:1637–41. [27] O’Brien SH, Ritchey AK, Smith KJ. A cost-utility analysis of treatment for acute childhood idiopathic thrombocytopenic purpura (ITP). Pediatr Blood Cancer 2007;48:173–80. [28] Briggs AH, Goeree R, Blackhouse G, et al. Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. Med Decis Making 2002;22:290–308. [29] Colowick AB, Bohn RL, Avorn J, et al. Immune tolerance induction in hemophilia patients with inhibitors: costly can be cheaper. Blood 2000;96:1698–702. [30] Nietert PJ, Abboud MR, Silverstein MD, et al. Bone marrow transplantation versus periodic prophylactic blood transfusion in sickle cell patients at high risk of ischemic stroke: a decision analysis. Blood 2000;95:3057–64. [31] Hankins J, Hinds P, Day S, et al. Therapy preference and decision-making among patients with severe sickle cell anemia and their families. Pediatr Blood Cancer 2007;48:705–10. [32] Klaassen RJ, Doyle JJ, Krahn MD, et al. Initial bone marrow aspiration in childhood idiopathic thrombocytopenia: decision analysis. J Pediatr Hematol Oncol 2001;23:511–8. [33] Centre for Review and Dissemination. National Health Service economic evaluation database. Available at: http://www.york.ac.uk/ubst/crd/crddatabases.htm. Accessed February 15, 2008. [34] Richardson WS, Detsky AS. Users’ guides to the medical literature. VII. How to use a clinical decision analysis. A. Are the results of the study valid Evidence-based medicine working group. JAMA 1995;273:1292–5. [35] Naimark D, Naglie G, Detsky AS. The meaning of life expectancy: what is a clinically significant gain J Gen Intern Med 1994;9:702–7. [36] Tsevat J, Weinstein MC, Williams LW, et al. Expected gains in life expectancy from various coronary heart disease risk factor modifications. Circulation 1991;83:1194–201. [37] Goel V. Decision analysis: applications and limitations. The health services research group. CMAJ 1992;147:413–7. [38] TreeAge Software, Inc. TreeAge software training. Available at: http://server.treeage.com/ treeagepro/training/index.asp. Accessed February 17, 2008. [39] Allen UD, Kirby MA, Goeree R. Cost-effectiveness of recombinant human erythropoietin versus transfusions in the treatment of zidovudine-related anemia in HIV-infected children. Pediatr AIDS HIV Infect 1997;8:4–11. [40] Killie MK, Kjeldsen-Kragh J, Husebekk A, et al. Cost-effectiveness of antenatal screening for neonatal alloimmune thrombocytopenia. BJOG 2007;114:588–95. [41] Mazumdar M, Heeney MM, Sox CM, et al. Preventing stroke among children with sickle cell anemia: an analysis of strategies that involve transcranial Doppler testing and chronic transfusion. Pediatrics 2007;120:e1107–16. [42] Panepinto JA, Magid D, Rewers MJ, et al. Universal versus targeted screening of infants for sickle cell disease: a cost-effectiveness analysis. J Pediatr 2000;136:201–8. [43] Thung SF, Grobman WA. The cost effectiveness of empiric intravenous immunoglobulin for the antepartum treatment of fetal and neonatal alloimmune thrombocytopenia. Am J Obstet Gynecol 2005;193:1094–9.
Page 2 and 3: Pediatr Clin N Am 55 (2008) xiii-xi
Page 4 and 5: Pediatr Clin N Am 55 (2008) 287-304
Page 6 and 7: DECISION ANALYSIS IN PEDIATRIC HEMA
Page 16 and 17: Nietert et al [30] Treatment of sic
Page 24 and 25: VENOUS THROMBOEMBOLISM IN CHILDREN
Page 42 and 43: PEDIATRIC ARTERIAL ISCHEMIC STROKE
Page 58 and 59: CARE OF PATIENTS WITH VASCULAR ANOM
Page 70 and 71:
CARE OF PATIENTS WITH VASCULAR ANOM
Page 72 and 73:
CARE OF PATIENTS WITH VASCULAR ANOM
Page 74 and 75:
358 RODRIGUEZ & HOOTS Fig. 1. X-lin
Page 76 and 77:
Table 1 Clotting factor concentrate
Page 78 and 79:
Table 1 (continued ) Factor VIII (o
Page 80 and 81:
364 RODRIGUEZ & HOOTS was administe
Page 82 and 83:
366 RODRIGUEZ & HOOTS Antifibrinoly
Page 84 and 85:
368 RODRIGUEZ & HOOTS infections an
Page 86 and 87:
370 RODRIGUEZ & HOOTS Fig. 3. Schem
Page 88 and 89:
372 RODRIGUEZ & HOOTS protein is no
Page 90 and 91:
374 RODRIGUEZ & HOOTS [2] Berntorp
Page 92 and 93:
376 RODRIGUEZ & HOOTS [42] Carcao M
Page 94 and 95:
378 ROBERTSON et al von Willebrand
Page 96 and 97:
380 ROBERTSON et al Fig. 2. A propo
Page 98 and 99:
382 ROBERTSON et al a heterogenous
Page 100 and 101:
384 ROBERTSON et al of considering
Page 102 and 103:
386 ROBERTSON et al Type 2M Type 2M
Page 104 and 105:
388 ROBERTSON et al Desmopressin is
Page 106 and 107:
390 ROBERTSON et al References [1]
Page 108 and 109:
392 ROBERTSON et al [46] Nesbitt IM
Page 110 and 111:
394 BLANCHETTE & BOLTON-MAGGS A key
Page 112 and 113:
396 BLANCHETTE & BOLTON-MAGGS recep
Page 114 and 115:
398 BLANCHETTE & BOLTON-MAGGS and p
Page 116 and 117:
400 BLANCHETTE & BOLTON-MAGGS Fig.
Page 118 and 119:
402 BLANCHETTE & BOLTON-MAGGS in di
Page 120 and 121:
404 BLANCHETTE & BOLTON-MAGGS the s
Page 122 and 123:
406 BLANCHETTE & BOLTON-MAGGS findi
Page 124 and 125:
408 BLANCHETTE & BOLTON-MAGGS as a
Page 126 and 127:
410 BLANCHETTE & BOLTON-MAGGS splen
Page 128 and 129:
412 BLANCHETTE & BOLTON-MAGGS with
Page 130 and 131:
414 BLANCHETTE & BOLTON-MAGGS react
Page 132 and 133:
416 BLANCHETTE & BOLTON-MAGGS [16]
Page 134 and 135:
Page 136 and 137:
Page 138 and 139:
422 FASANO & LUBAN of storage and t
Page 140 and 141:
424 FASANO & LUBAN Leukocyte reduct
Page 142 and 143:
426 FASANO & LUBAN RBCs is decrease
Page 144 and 145:
Table 1 Blood component characteris
Page 146 and 147:
430 FASANO & LUBAN Alloimmunization
Page 148 and 149:
432 FASANO & LUBAN of individual un
Page 150 and 151:
434 FASANO & LUBAN patients have an
Page 152 and 153:
436 FASANO & LUBAN adults; therefor
Page 154 and 155:
438 FASANO & LUBAN [21]. Meta-analy
Page 156 and 157:
440 FASANO & LUBAN Pretransfusion m
Page 158 and 159:
442 FASANO & LUBAN [55,56]. This is
Page 160 and 161:
444 FASANO & LUBAN [20] Roseff SD,
Page 162 and 163:
Pediatr Clin N Am 55 (2008) 447-460
Page 164 and 165:
THALASSEMIA UPDATE 449 hypochromia
Page 166 and 167:
THALASSEMIA UPDATE 451 Fig. 1. Chan
Page 168 and 169:
THALASSEMIA UPDATE 453 delivery of
Page 170 and 171:
THALASSEMIA UPDATE 455 thromboses i
Page 172 and 173:
THALASSEMIA UPDATE 457 On the basis
Page 174 and 175:
THALASSEMIA UPDATE 459 [31] Kan YW,
Page 176 and 177:
Page 178 and 179:
ORAL IRON CHELATORS 463 large iron-
Page 180 and 181:
ORAL IRON CHELATORS 465 of 50 child
Page 182 and 183:
ORAL IRON CHELATORS 467 Table 2 Com
Page 184 and 185:
ORAL IRON CHELATORS 469 use in Nort
Page 186 and 187:
ORAL IRON CHELATORS 471 needed to d
Page 188 and 189:
ORAL IRON CHELATORS 473 in liver fi
Page 190 and 191:
ORAL IRON CHELATORS 475 in the lowe
Page 192 and 193:
ORAL IRON CHELATORS 477 Other oral
Page 194 and 195:
ORAL IRON CHELATORS 479 [12] Borgna
Page 196 and 197:
ORAL IRON CHELATORS 481 [55] Wonke
Page 198 and 199:
Page 200 and 201:
HYDROXYUREA FOR CHILDREN WITH SICKL
Page 202 and 203:
Page 204 and 205:
Page 206 and 207:
Page 208 and 209:
Fig. 1. Guideline for initiating, m
Page 210 and 211:
Page 212 and 213:
Page 214 and 215:
Page 216 and 217:
Page 218 and 219:
504 TRACY & RICE congenital spheroc
Page 220 and 221:
506 TRACY & RICE and antibodies aga
Page 222 and 223:
508 TRACY & RICE limited splenic vo
Page 224 and 225:
510 TRACY & RICE constitutes the pi
Page 226 and 227:
512 TRACY & RICE German experience
Page 228 and 229:
514 TRACY & RICE Table 1 Effect of
Page 230 and 231:
516 TRACY & RICE decreased bilirubi
Page 232 and 233:
518 TRACY & RICE [13] Bader-Meunier
show all

Pediatric Clinics of North America - CIPERJ

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?